Aardvark Therapeutics (AARD) Competitors $10.82 -0.29 (-2.61%) As of 11:37 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock AARD vs. CRON, REPL, DNTH, XERS, KALV, ABUS, ANAB, ARVN, TRVI, and CDXCShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Cronos Group (CRON), Replimune Group (REPL), Dianthus Therapeutics (DNTH), Xeris Biopharma (XERS), KalVista Pharmaceuticals (KALV), Arbutus Biopharma (ABUS), AnaptysBio (ANAB), Arvinas (ARVN), Trevi Therapeutics (TRVI), and ChromaDex (CDXC). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. Cronos Group Replimune Group Dianthus Therapeutics Xeris Biopharma KalVista Pharmaceuticals Arbutus Biopharma AnaptysBio Arvinas Trevi Therapeutics ChromaDex Cronos Group (NASDAQ:CRON) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, community ranking, earnings, dividends, analyst recommendations, valuation and profitability. Do insiders and institutionals have more ownership in CRON or AARD? 8.7% of Cronos Group shares are held by institutional investors. 6.9% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable valuation & earnings, CRON or AARD? Aardvark Therapeutics has lower revenue, but higher earnings than Cronos Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCronos Group$117.62M6.14-$73.96M$0.1018.75Aardvark TherapeuticsN/AN/AN/AN/AN/A Do analysts prefer CRON or AARD? Cronos Group currently has a consensus target price of $3.50, suggesting a potential upside of 86.67%. Aardvark Therapeutics has a consensus target price of $31.50, suggesting a potential upside of 191.94%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CRON or AARD more profitable? Aardvark Therapeutics has a net margin of 0.00% compared to Cronos Group's net margin of -42.65%. Aardvark Therapeutics' return on equity of 0.00% beat Cronos Group's return on equity.Company Net Margins Return on Equity Return on Assets Cronos Group-42.65% -2.56% -2.47% Aardvark Therapeutics N/A N/A N/A Does the MarketBeat Community favor CRON or AARD? Cronos Group received 457 more outperform votes than Aardvark Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Aardvark Therapeutics an outperform vote while only 61.13% of users gave Cronos Group an outperform vote. CompanyUnderperformOutperformCronos GroupOutperform Votes46461.13% Underperform Votes29538.87% Aardvark TherapeuticsOutperform Votes7100.00% Underperform VotesNo Votes Does the media favor CRON or AARD? In the previous week, Cronos Group had 1 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 3 mentions for Cronos Group and 2 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.94 beat Cronos Group's score of 0.52 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAardvark Therapeutics beats Cronos Group on 8 of the 13 factors compared between the two stocks. Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$234.10M$6.79B$5.53B$7.99BDividend YieldN/A3.05%5.11%4.23%P/E RatioN/A7.4422.6518.64Price / SalesN/A244.75401.98103.80Price / CashN/A65.8538.1834.62Price / BookN/A6.536.754.30Net IncomeN/A$143.43M$3.22B$248.44M7 Day Performance31.27%2.23%1.66%1.81%1 Month Performance30.16%7.19%4.17%4.40%1 Year PerformanceN/A-2.24%16.17%5.97% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark TherapeuticsN/A$10.82-2.6%$31.50+191.1%N/A$234.75MN/A0.0018CRONCronos Group1.5295 of 5 stars$1.85+3.4%$3.50+89.2%-36.1%$713.00M$117.62M-14.23450Upcoming EarningsREPLReplimune Group4.1946 of 5 stars$9.06+2.6%$19.43+114.4%+54.0%$697.76MN/A-2.95210Positive NewsDNTHDianthus Therapeutics1.7382 of 5 stars$21.23-1.5%$54.33+155.9%+2.3%$682.04M$6.24M-8.4980Upcoming EarningsNews CoveragePositive NewsXERSXeris Biopharma3.5779 of 5 stars$4.28+3.6%$6.10+42.5%+161.1%$658.86M$203.07M-9.51290Upcoming EarningsNews CoveragePositive NewsKALVKalVista Pharmaceuticals4.38 of 5 stars$12.88+3.5%$24.83+92.8%+21.3%$640.34MN/A-3.54100Positive NewsABUSArbutus Biopharma2.0068 of 5 stars$3.34+3.1%$5.50+64.7%+30.0%$639.54M$6.17M-7.7790ANABAnaptysBio2.5266 of 5 stars$20.61+0.9%$33.63+63.1%-8.7%$632.05M$91.28M-3.39100Upcoming EarningsNews CoveragePositive NewsARVNArvinas3.3962 of 5 stars$9.14+0.8%$34.33+275.6%-69.7%$628.58M$263.40M-3.30420Earnings ReportUpcoming EarningsShort Interest ↑News CoveragePositive NewsTRVITrevi Therapeutics3.6011 of 5 stars$6.35+1.3%$17.56+176.6%+135.8%$613.93MN/A-14.4320Upcoming EarningsNews CoveragePositive NewsCDXCChromaDex2.3375 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies CRON Alternatives REPL Alternatives DNTH Alternatives XERS Alternatives KALV Alternatives ABUS Alternatives ANAB Alternatives ARVN Alternatives TRVI Alternatives CDXC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AARD) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
